IMPACT Therapeutics Australia

Impact Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics, with a primary focus on the DNA Damage Response (DDR) pathway. The company has established a comprehensive DDR pipeline that includes PARP, Wee1, ATR, and DNA-PK inhibitors, positioning itself as a leader in synthetic lethality research. Its lead candidate, senaparib, has demonstrated significant efficacy in clinical trials for ovarian cancer and is being developed both as a monotherapy and in combination with other agents. Impact Therapeutics Australia serves as a key regional entity for conducting clinical trials, leveraging Australia's robust clinical research infrastructure to advance its global development strategy.